Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma

NCT00752570 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT00752570
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00752570 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2008
Completion date
June 30, 2012
Enrollment
144 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, carcinoma, colon cancer, colorectal cancer, gastrointestinal cancer, metastases, metastatic cancer, metastatic colorectal cancer, oncology, rectal cancer